RNS Number : 9975D


03 November 2020


("IXICO" or the "Company")

Additional Alzheimer's disease contracts with new and existing large pharma clients

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Alzheimer's disease (AD) clinical trials.

The new contracts include a Phase I study in Alzheimer's disease with a new biotechnology customer, an expansion contract for a Phase II trial with an existing biotechnology company and the initiation of an open-label extension phase III trial with an existing large pharmaceutical company.

The contracts build on the strength IXICO has in AD clinical trials and are in addition to the partnership with the Global Alzheimer's Platform which the Company announced on World Alzheimer's Day, 21 September 2020.

These contracts were included in management's expectations of performance for the coming year and contribute to the Company's strong order book. These contracts relate to trials at different stages of drug development and are with several different customers, strengthening diversification in the Company's order book.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "Today there are 50 million people worldwide that suffer with Alzheimer's and other forms of dementias. There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer's disease. With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support some of these potential treatments that one day may be in the hands of Alzheimer's patients worldwide. "

For further information please contact:

 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
 Michael F Johnson / Russell Kerr 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
 Alice Woodings 


IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 03, 2020 02:00 ET (07:00 GMT)